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ABSTRACT 
The present work relates to development and validation of simple, precise and rapid high-performance liquid chromatographic (HPLC) method 
for the analysis of Chlorthalidone in tablet dosage form. Method was developed for qualitative and quantitative estimation of Chlorthalidone in 
tablet dosage form. The chromatographic separation was achieved by using mobile phase 20 mM potassium dihydrogen orthophosphate buffer 
pH 4.0: methanol (30:70 %v/v) on HiQ Sil C8 (4.6 mm*250 mm* 5μm) column. The mobile phase was pumped at a flow rate of 1.0 ml/min and 
the eluent was monitored at 230 nm. Retention time was 3.334±0.042 min. Linearity was observed in the concentration range of 5-30 μg/ml 
with a correlation coefficient (R2) of 0.9915. All the parameters were validated as per ICH guidelines and found to be suitable for routine 
analysis of drug in pharmaceutical dosage form. 
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INTRODUCTION 
Chlorthalidone is a long acting thiazide-like diuretic of the 
sulfamoylbenzamide class that is devoid of 
the benzothiadiazine structure. Chlorthalidone directly 
inhibits sodium and chloride reabsorption on the luminal 
membrane of the early segment in the distal convoluted 
tubule (DCT) in the kidney. This leads to an increase 
in sodium, chloride, bicarbonate, and potassium secretion 
resulting in the excretion of water. In addition, this agent, 
like other thiazide diuretics, decreases calcium and uric 
acid secretion. In addition, this agent inhibits many carbonic 
anhydrase (CA) isoenzymes.Chlorthalidone is considered 
first-line therapy for management of uncomplicated 
hypertension as there is strong evidence from meta-analyses 
that thiazide diuretics such as Chlorthalidone reduce the risk 
of stroke, myocardial infarction, heart failure, and 
cardiovascular all-cause mortality in patients with 
hypertension. Chlorthalidone is used in the treatment of high 
blood pressure, edema and congestive heart failure [1-2]. 
Chlorthalidone is chemically described as 2-chloro-5-(2, 3-
dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl) 
benzenesulfonamide [3]. 
 
Figure I: Chemical structure of Chlorthalidone 
Literature review indicated that few UV spectrophotometric 
[4-6], HPLC [7-10] methods was reported for estimation of drug 
as individual or in combination with other drugs. 
literature survey  reveals that the data of reported HPLC 
methods is incomplete hence based on these observations 
we have developed HPLC method and validated as per 
International Conference on Harmonization Guidelines[12] for 
estimation of Chlorthalidone. 
MATERIALS AND METHODS 
Reagents and chemicals 
Chlorthalidone tablets I.P labeled to contain Chlorthalidone 
6.50 mg were purchased from local market. Methanol (AR 
grade), Methanol (HPLC grade), potassium dihydrogen 
phosphate, ortho-phosphoric acid, HPLC Grade water was 
used in study. 
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Preparation of standard stock solution:  
Standard stock solution of drug was prepared by dissolving 
10 mg of drug in 10 ml of methanol to get concentration of 
1000 µg/ml. From this solution 5 ml was taken in 50 ml 
volumetric flask and volume was made up with methanol to 
get concentration of solution 100 µg/ml. Further 1 ml of this 
solution was diluted to 10 ml with mobile phase to get 
concentration of solution 10 µg/ml. 
Selection of detection wavelength: 
From the standard stock solution (1000 μg/ml) further 
dilutions was made using methanol and scanned over the 
range of 200-400 nm and the spectra was obtained. It was 
observed that the drug showed linear, stable and 
considerable absorbance at 230 nm. Representative UV 
spectrum was obtained shown in Figure II. 
 
Figure II:  UV Spectrum of Chlorthalidone (10 µg/ml) 
Selection of mobile phase: 
The standard solution of Chlorthalidone (10 µg/ml) was 
injected into the HPLC system. Solvents 20 mM potassium 
dihydrogen orthophosphate buffer (pH 4) and methanol 
(30:70v/v) was chosen as the mobile phase, which gave 
acceptable peak parameters. Representative HPLC 
chromatograph is given in Figure III 
 
 
Figure III: Chromatogram of Chlorthalidone (10 µg/ml) 
 
Preparation of 20 mM potassium dihydrogen phosphate 
buffer (pH 4) and mobile phase: 
20 mM potassium dihydrogen phosphate buffer (pH 4) was 
prepared by dissolving 272 mg of potassium dihydrogen 
phosphate in 200 ml of HPLC grade water and pH of the 
solution was checked. pH was adjusted to 4 by ortho-
phosphoric acid. Mobile phase was prepared by mixing 
potassium dihydrogen phosphate buffer (pH 4) and 
methanol in the ratio of 30:70 v/v. It was then filtered 
through 0.45µm nylon 6, membrane filter and sonicated for 
15 min 
Preparation of sample solution: 
A content of 20 tablets was weighed and triturated to 
powder. A quantity of powder equivalent to 10 mg of 
Chlorthalidone was transferred to a 10 ml volumetric flask 
containing 10 ml of methanol. The mixture was ultra-
sonicated for 15 min and the resulting sample stock solution 
was filtered with Whatman filter paper 41 and the volume 
was made up with the methanol to get concentration of 1000 
µg/ml. Further dilution were made to get concentration 10 
µg/ml. 
 
 
 
RESULTS AND DISCUSSION 
Validation of analytical method [11]:  
Linearity: 
From the standard stock solution (1000 μg/ml) of 
Chlorthalidone, solution was prepared containing 100 μg/ml 
with methanol. This solution was further used to prepare 
range of solution containing six different concentrations by 
using mobile phase. The linearity (relationship between peak 
area and concentration) was determined by analyzing six 
solutions over the concentration range of 5-30 µg/ml. The 
equation of calibration curve was found to be y = 172250x - 
102173. The peak area of drug was plotted against the 
corresponding concentrations to obtain the calibration curve 
as shown in Figure IV. The results obtained are shown in 
Table I 
 
Figure IV: Calibration Curve of Chlorthalidone
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Table I: Linearity study data for Chlorthalidone 
Replicates 
 
Concentrations of Chlorthalidone 
5 μg/ml 10 μg/ml 15 μg/ml 20 μg/ml 25 μg/ml 30 μg/ml 
Peak Area 
1 865843.2 1639680 2480303 3124996 4221263 5352837 
2 862836 1679193 2409482 3176863 4077366 5267557 
3 844065.7 1632744 2409482 3144434 4025417 5360332 
4 860010.8 1639680 2373585 3226756 4024086 5318589 
5 865843.2 1639680 2399873 3124996 4121263 5122837 
6 892836 1660599 2380303 3176863 4077366 5287557 
Mean 865239.2 1660599 2408838 3162485 4091127 5284951 
Std. Dev. 15771.75 26072.96 38066.79 39194.09 73531.66 87192.51 
%RSD 1.82 1.57 1.58 1.23 1.79 1.64 
 
Precision: 
The precision of the method was demonstrated by intra-day 
and inter-day variation studies. In the Intra-day studies, 3 
replicates of 3 different concentrations was analyzed in a 
day and percentage RSD was calculated. For the inter-day 
variation studies, 3 different concentrations was analyzed on 
3 consecutive days and percentage RSD was calculated.The 
results obtained are shown in Table II. 
 
Table II: Intra-day and Inter-day variation studies data forChlorthalidone. 
Conc. 
(µg/ml) 
Intra-day precision * Inter-day precision * 
Peak area % RSD Peak area % RSD 
10 
1823101.316 
0.60 
1852005.012 
1.38 1819680.109 1805020.147 
1839193.102 1835120.596 
15 
2709482 
1.33 
2719622.251 
1.47 2649951 2647745.153 
2709523 2705902.457 
25 
4521263.115 
1.37 
4392567.115 
1.15 4421356.005 4457635.005 
4528747.103 4490727.103 
 
Limit of detection (LOD) and limit of quantitation (LOQ): 
From the linearity data the LOD and LOQ was calculated, 
using the formula LOD = 3.3 σ/S and LOQ = 10 σ/S, where  
σ = standard deviation of the response at lowest 
concentration or standard deviation y intercept 
S = average of slope of the calibration curve.
Table III: LOD and LOQ of Chlorthalidone 
Method Avg slope SD LOD (µg/ml) LOQ (µg/ml) 
1.Using S.D of the response at lowest concentration 145829.16 15771.74 0.357 1.082 
2. Using S.D  of y-intercept 145829.16 35107.64 0.794 2.407 
 
Specificity: 
The specificity of the method was ascertained by peak purity 
profile studies. The peak purity values were found to be 
more than 0.996, indicating the no interference of any other 
peak of degradation product, impurity or matrix.  
Accuracy:  
To check accuracy of the method, recovery studies were 
carried out at three different levels around 50, 100 and 150 
%. Basic concentration of sample solution chosen was 10 
µg/ml. % recovery was determined from linearity equation. 
The results obtained are shown in Table IV 
 
Table IV: Accuracy of Chlorthalidone. 
Level% 
Sample 
(μg/ml) 
Standard 
(μg/ml) 
Area %Recovery * 
 
50 10 05 
2799837.603 
98.68-101.85% 2707995.207 
2699289.618 
100 10 10 
3533289.618 
99.60-101.94% 3614057.529 
3555662.151 
150 10 15 
4473624.401 
100.72-101.83% 4487091.839 
4439326.564 
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Assay: 
Twenty tablets were weighed and crushed in mortar by 
pestle. Powder equivalent to 10 mg of Chlorthalidone was 
accurately weighed and transferred into a 10 ml volumetric 
flask and volume was made up with methanol as mentioned 
under section preparation of stock solution (1000 µg/ml). 
The volumetric flask was sonicated for 15 min to enable 
complete dissolution of Chlorthalidone and the solution was 
filtered through 0.45 µm whatmann filter paper. From the 
filtrate further dilution was made with methanol to get 100 
µg/ml solution. Finally this solution was further diluted with 
mobile phase to yield a concentration of 10 µg/ml. Sample 
solution was injected and area was recorded. The procedure 
was repeated for six times. Concentration and % recovery 
was determined from linear equation. The results obtained 
are shown in Table V. 
 
Table V: Assay of marketed formulation 
Sr. 
No. 
Peak 
Area 
Amount Recovered 
%Recovery 
Mean  ± % 
RSD (μg/ml) 
1 1812734 9.93 100.8 
100.26 
2 1819993 9.97 98.64 
3 1826278 10 99.12 
4 1810798 9.92 101.6 
5 1855520 10.12 99.36 
6 1850574 10.15 101.4 
 
Robustness: 
Robustness of the method was checked by carrying out the 
analysis under conditions during which flow rate (± 0.5% 
Composition), detection wavelength (± 1 nm) was altered 
and the effect on the area was noted. Robustness of the 
method checked after deliberate alterations of the analytical 
parameters showed that areas of peaks of interest remained 
unaffected by small changes of the operational parameters 
indicating that the method is robust. 
Table VI: Robustness study. 
% RSD Found for Robustness Study (peak area) 
Flow Rate Detection Wavelength (± 1 nm) 
0.95 1 1.05 229 230 231 
1.324 1.61 1.2 1.518 1.618 1.326 
CONCLUSION  
All the parameters were validated as per ICH guidelines for 
the method validation and found to be suitable for routine 
analysis of drug in pharmaceutical dosage forms. The result 
of linearity, accuracy, precision proved to be within limits 
with lower limits of detection and quantification. Robustness 
of method was confirmed as no significant difference was 
observed on analysis by subjecting the method to slight 
change in the method condition. Assay results obtained by 
proposed method are in good agreement. 
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